116 related articles for article (PubMed ID: 38415346)
41. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
[TBL] [Abstract][Full Text] [Related]
42. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
43. Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management.
McGee RB; Oak N; Harrison L; Xu K; Nuccio R; Blake AK; Mostafavi R; Lewis S; Taylor LM; Kubal M; Ouma A; Hines-Dowell SJ; Cheng C; Furtado LV; Nichols KE
Clin Cancer Res; 2023 Apr; 29(7):1243-1251. PubMed ID: 36693186
[TBL] [Abstract][Full Text] [Related]
44. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer.
Okawa Y; Iwasaki Y; Johnson TA; Ebata N; Inai C; Endo M; Maejima K; Sasagawa S; Fujita M; Matsuda K; Murakami Y; Nakamura T; Hirano S; Momozawa Y; Nakagawa H
J Hepatol; 2023 Feb; 78(2):333-342. PubMed ID: 36243179
[TBL] [Abstract][Full Text] [Related]
45. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer.
Hińcza K; Kowalik A; Kowalska A
Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31247975
[TBL] [Abstract][Full Text] [Related]
46. Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial non-medullary thyroid cancer.
Raitila A; Georgitsi M; Bonora E; Vargiolu M; Tuppurainen K; Mäkinen MJ; Vierimaa O; Salmela PI; Launonen V; Vahteristo P; Aaltonen LA; Romeo G; Karhu A
J Endocrinol Invest; 2009 May; 32(5):426-9. PubMed ID: 19794292
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer.
Ku GY; Kemel Y; Maron SB; Chou JF; Ravichandran V; Shameer Z; Maio A; Won ES; Kelsen DP; Ilson DH; Capanu M; Strong VE; Molena D; Sihag S; Jones DR; Coit DG; Tuvy Y; Cowie K; Solit DB; Schultz N; Hechtman JF; Offit K; Joseph V; Mandelker D; Janjigian YY; Stadler ZK
JAMA Netw Open; 2021 Jul; 4(7):e2114753. PubMed ID: 34251444
[TBL] [Abstract][Full Text] [Related]
48. Germline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With Mesothelioma.
Mitchell OD; Gilliam K; Del Gaudio D; McNeely KE; Smith S; Acevedo M; Gaduraju M; Hodge R; Ramsland ASS; Segal J; Das S; Hathaway F; Bryan DS; Tawde S; Galasinski S; Wang P; Tjota MY; Husain AN; Armato SG; Donington J; Ferguson MK; Turaga K; Churpek JE; Kindler HL; Drazer MW
JAMA Netw Open; 2023 Aug; 6(8):e2327351. PubMed ID: 37556141
[TBL] [Abstract][Full Text] [Related]
49. Prevalence of Thyroid Nodules and Thyroid Cancer in Individuals with a First-Degree Family History of Non-Medullary Thyroid Cancer: A Cross-Sectional Study Based on Sonographic Screening.
Grani G; Lamartina L; Montesano T; Giacomelli L; Biffoni M; Trulli F; Filetti S; Durante C
Thyroid; 2022 Nov; 32(11):1392-1401. PubMed ID: 36097761
[No Abstract] [Full Text] [Related]
50. Prevalence of (Epi)genetic Predisposing Factors in a 5-Year Unselected National Wilms Tumor Cohort: A Comprehensive Clinical and Genomic Characterization.
Hol JA; Kuiper RP; van Dijk F; Waanders E; van Peer SE; Koudijs MJ; Bladergroen R; van Reijmersdal SV; Morgado LM; Bliek J; Lombardi MP; Hopman S; Drost J; de Krijger RR; van den Heuvel-Eibrink MM; Jongmans MCJ
J Clin Oncol; 2022 Jun; 40(17):1892-1902. PubMed ID: 35230882
[TBL] [Abstract][Full Text] [Related]
51. Germline whole genome sequencing in adults with multiple primary tumors.
Wang Y; Ding Q; Prokopec S; Farncombe KM; Bruce J; Casalino S; McCuaig J; Szybowska M; van Engelen K; Lerner-Ellis J; Pugh TJ; Kim RH
Fam Cancer; 2023 Oct; 22(4):513-520. PubMed ID: 37481477
[TBL] [Abstract][Full Text] [Related]
52. Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non-medullary thyroid cancer.
Crezee T; Tesselaar MH; Nagarajah J; Corver WE; Morreau J; Pritchard C; Kimura S; Kuiper JG; van Engen-van Grunsven I; Smit JWA; Netea-Maier RT; Plantinga TS
Cell Oncol (Dordr); 2021 Jun; 44(3):611-625. PubMed ID: 33534128
[TBL] [Abstract][Full Text] [Related]
53. Novel Candidate
Andrés-Zayas C; Suárez-González J; Chicano-Lavilla M; Bastos Oreiro M; Rodríguez-Macías G; Font López P; Osorio Prendes S; Oarbeascoa Royuela G; García Ramírez P; Nieves Salgado R; Gómez-Centurión I; Carbonell Muñoz D; Muñiz P; Kwon M; Díez-Martín JL; Buño I; Martínez-Laperche C
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765901
[TBL] [Abstract][Full Text] [Related]
54. The HABP2 G534E polymorphism does not increase nonmedullary thyroid cancer risk in Hispanics.
Bohórquez ME; Estrada AP; Stultz J; Sahasrabudhe R; Williamson J; Lott P; Duque CS; Donado J; Mateus G; Bolaños F; Vélez A; Echeverry M; Carvajal-Carmona LG
Endocr Connect; 2016 May; 5(3):123-7. PubMed ID: 27097599
[TBL] [Abstract][Full Text] [Related]
55. Risk of thyroid cancer in first-degree relatives of patients with non-medullary thyroid cancer by histology type and age at diagnosis: a joint study from five Nordic countries.
Fallah M; Pukkala E; Tryggvadottir L; Olsen JH; Tretli S; Sundquist K; Hemminki K
J Med Genet; 2013 Jun; 50(6):373-82. PubMed ID: 23585692
[TBL] [Abstract][Full Text] [Related]
56. The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients.
Wagener R; Walter C; Auer F; Alzoubi D; Hauer J; Fischer U; Varghese J; Dugas M; Borkhardt A; Brozou T
Int J Cancer; 2023 Apr; 152(7):1388-1398. PubMed ID: 36468172
[TBL] [Abstract][Full Text] [Related]
57. Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
Yehia L; Ni Y; Sesock K; Niazi F; Fletcher B; Chen HJL; LaFramboise T; Eng C
PLoS Genet; 2018 Apr; 14(4):e1007352. PubMed ID: 29684080
[TBL] [Abstract][Full Text] [Related]
58. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
[TBL] [Abstract][Full Text] [Related]
59. Implications of Incidental Germline Findings Identified In the Context of Clinical Whole Exome Sequencing for Guiding Cancer Therapy.
Schneider BP; Stout LA; Philips S; Schroeder C; Scott SF; Hunter C; Kassem N; Kiel PJ; Radovich M
JCO Precis Oncol; 2020 Nov; 4():1109-1121. PubMed ID: 35050776
[TBL] [Abstract][Full Text] [Related]
60. Nationwide germline whole genome sequencing of 198 consecutive pediatric cancer patients reveals a high incidence of cancer prone syndromes.
Byrjalsen A; Hansen TVO; Stoltze UK; Mehrjouy MM; Barnkob NM; Hjalgrim LL; Mathiasen R; Lautrup CK; Gregersen PA; Hasle H; Wehner PS; Tuckuviene R; Sackett PW; Laspiur AO; Rossing M; Marvig RL; Tommerup N; Olsen TE; Scheie D; Gupta R; Gerdes AM; Schmiegelow K; Wadt K
PLoS Genet; 2020 Dec; 16(12):e1009231. PubMed ID: 33332384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
